文献速递泌尿男性生殖肿瘤

肉瘤样肾细胞癌一线治疗再定义:免疫检查点抑制剂随机临床试验荟萃分析

Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors.
PubMed 文献 · Eur J Cancer · 2020-07-23

该荟萃分析纳入4项II/III期随机临床试验共467例肉瘤样肾细胞癌患者,比较免疫检查点抑制剂联合方案与舒尼替尼的疗效。结果显示ICI联合方案较舒尼替尼显著改善无进展生存和总生存,降低进展与死亡风险超过40%,客观缓解率超过50%,完全缓解发生率为11%。

要点

  • ICI联合方案较舒尼替尼显著改善sRCC患者PFS和OS,风险降低超过40%。
  • ICI联合方案ORR超过50%,舒尼替尼为20%,ORR获益风险比为2.15。
  • 免疫治疗显著提高完全缓解可能性(RR=8.15),完全缓解发生率为11%。

核心结论

  • 数据支持ICI联合方案用于sRCC治疗,并重新定义一线治疗。

研究设计与样本

  • 检索MEDLINE/PubMed、Cochrane Library和ASCO会议摘要中的II期或III期随机临床试验。
  • 最终纳入4项研究,共467例患者,其中ICI联合组226例,对照组舒尼替尼241例。

主要发现

  • ICI联合方案较舒尼替尼改善PFS,进展风险降低超过40%(HR=0.56;p<0.0001)。
  • ICI联合方案较舒尼替尼改善OS,死亡风险降低超过40%(HR=0.56;p=0.001)。
  • ICI联合方案ORR超过50%,对照组舒尼替尼为20%,达到ORR的风险比为2.15(p<0.00001)。
  • 免疫治疗显著提高完全缓解可能性(RR=8.15;p=0.0002),完全缓解发生率为11%。

临床怎么用

  • sRCC一线治疗可优先考虑含免疫检查点抑制剂的联合方案而非舒尼替尼。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sarcomatoid renal cell carcinoma (sRCC) represents a rare form of renal cell carcinoma marked by an aggressive biology, poor prognosis and little benefit from anti-angiogenic targeted therapy. More promising results come from the recent therapeutic strategy based on immune checkpoint inhibitor (ICI) combinations. MATERIALS AND METHODS: For this meta-analysis, we searched MEDLINE/PubMed, the Cochrane Library and American Society of Medical Oncology (ASCO) Meeting abstracts for phase II or III randomised clinical trials. Data extraction was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis statement. The hazard ratios (HRs) for progression-free survival (PFS) and overall survival (OS) with the relative 95% confidence intervals were extracted from studies. Summary HRs were calculated using random- or fixed-effects models, depending on the heterogeneity of the included studies. RESULTS: Four studies were selected for final analysis, including 467 patients (226 treated in with ICI combinations and 241 received sunitinib in the control arms). ICI-based combinations were associated with an improved PFS and OS compared with sunitinib, with a reduction of more than 40% of progression (HR = 0.56; p < 0.0001) and mortality (HR = 0.56; p = 0.001) risk. Moreover, ICI-based combinations are associated with a objective response rate (ORR) of more than 50% (versus 20% with sunitinib), corresponding to a doubled risk of achieving an ORR compared with controls (relative risk [RR] = 2.15; p < 0.00001). Finally, immunotherapy significantly increased the possibility to obtain complete responses (RR = 8.15, p = 0.0002) with an incidence of 11%. CONCLUSION: Our data support the efficacy of ICI-based combinations for sRCC therapy, redefining the first-line treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Iacovelli R, Ciccarese C, Bria E, et al. Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020. PMID: 32712550. doi:10.1016/j.ejca.2020.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。